Literature DB >> 27324761

Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.

Nathan P Wiederhold1, Laura Kovanda2, Laura K Najvar3, Rosie Bocanegra3, Marcos Olivo3, William R Kirkpatrick3, Thomas F Patterson3.   

Abstract

We evaluated the efficacy of isavuconazole against cryptococcal meningitis. Treatment with either oral isavuconazole (120 mg/kg and 240 mg/kg twice a day [BID]) or fluconazole as the positive control significantly improved survival in mice infected intracranially with either Cryptococcus neoformans USC1597 or H99 and significantly reduced brain fungal burdens for both isolates. Concentrations of isavuconazole in plasma and brain tissue also demonstrated that the greatest improvements in survival and fungal burden were associated with elevated exposures.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27324761      PMCID： PMC4997854          DOI： 10.1128/AAC.00229-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method.

Authors:  A Espinel-Ingroff; A Chowdhary; G M Gonzalez; J Guinea; F Hagen; J F Meis; G R Thompson; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

2.  Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.

Authors:  Seyedmojtaba Seyedmousavi; Roger J M Brüggemann; Jacques F Meis; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

3.  Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis.

Authors:  M H Nguyen; L K Najvar; C Y Yu; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

Authors:  Alexander J Lepak; Karen Marchillo; Jamie VanHecker; Daniel Diekema; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

5.  Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.

Authors:  Nathan P Wiederhold; Laura K Najvar; Rosie Bocanegra; William R Kirkpatrick; Tania C Sorrell; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2012-11-19       Impact factor: 5.191

6.  In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.

Authors:  Michael A Pfaller; Shawn A Messer; Paul R Rhomberg; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-06-05       Impact factor: 5.948

7.  Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.

Authors:  M A Pfaller; P R Rhomberg; S A Messer; R N Jones; M Castanheira
Journal:  Diagn Microbiol Infect Dis       Date:  2015-04-29       Impact factor: 2.803

8.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

9.  Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Jürgen Maares; Markus Heep; Jochen Spickerman; Erhard Weidekamm; Tom Brown; Michael Roehrle
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938

10.  Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.

Authors:  George R Thompson; Adrian Rendon; Rodrigo Ribeiro Dos Santos; Flavio Queiroz-Telles; Luis Ostrosky-Zeichner; Nkechi Azie; Rochelle Maher; Misun Lee; Laura Kovanda; Marc Engelhardt; Jose A Vazquez; Oliver A Cornely; John R Perfect
Journal:  Clin Infect Dis       Date:  2016-05-11       Impact factor: 9.079
View more
  17 in total

Review 1.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

2.  Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for In Vitro Antifungal Susceptibility Testing of Cryptococcus neoformans.

Authors:  Fatima Zohra Delma; Abdullah M S Al-Hatmi; Jochem B Buil; Hein van der Lee; Marlou Tehupeiory-Kooreman; G Sybren de Hoog; Joseph Meletiadis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

3.  Isavuconazole Diffusion in Infected Human Brain.

Authors:  Claire Rouzaud; Vincent Jullien; Anne Herbrecht; Bruno Palmier; Simona Lapusan; Marjolaine Morgand; Romain Guéry; Amélie Dureault; François Danion; Stéphanie Puget; Lauriane Goldwirt; Fanny Lanternier; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.

Authors:  Matthew W McCarthy; Brad Moriyama; Ruta Petraitiene; Thomas J Walsh; Vidmantas Petraitis
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

5.  Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans.

Authors:  Elizabeth W Tucker; Lisa Pieterse; Matthew D Zimmerman; Zarir F Udwadia; Charles A Peloquin; Maria Tarcela Gler; Shashank Ganatra; Jeffrey A Tornheim; Prerna Chawla; Janice C Caoili; Brittaney Ritchie; Sanjay K Jain; Véronique Dartois; Kelly E Dooley
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

6.  Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT.

Authors:  Martin Schmidt-Hieber; Dan Engelhard; Andrew Ullmann; Per Ljungman; Johan Maertens; Rodrigo Martino; Montserrat Rovira; Peter J Shaw; Christine Robin; Maura Faraci; Jenny Byrne; Kerstin Schäfer-Eckart; Hermann Einsele; Edgar Faber; Luigi Rigacci; Riccardo Saccardi; Aitana Balaguer-Rosello; Cecilia Isaksson; Maximilian Christopeit; Gloria Tridello; Junfeng Wang; Nina Knelange; Malgorzata Mikulska; Simone Cesaro; Jan Styczynski
Journal:  J Neurol       Date:  2019-10-29       Impact factor: 4.849

7.  In Vivo Efficacy of VT-1129 against Experimental Cryptococcal Meningitis with the Use of a Loading Dose-Maintenance Dose Administration Strategy.

Authors:  Nathan P Wiederhold; Xin Xu; Amy Wang; Laura K Najvar; Edward P Garvey; Elizabeth A Ottinger; Asaf Alimardanov; Jim Cradock; Mark Behnke; William J Hoekstra; Stephen R Brand; Robert J Schotzinger; Rosie Jaramillo; Marcos Olivo; William R Kirkpatrick; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

8.  Extrapolating Antifungal Animal Data to Humans - Is it reliable?

Authors:  Victoria M Stevens; Scott W Mueller; Paul M Reynolds; Robert MacLaren; Tyree H Kiser
Journal:  Curr Fungal Infect Rep       Date:  2020-01-16

9.  Successful Treatment of Cryptococcal Meningitis and Cryptococcoma with Isavuconazole in a Patient Living with HIV.

Authors:  Brendan O'Kelly; Aia Mohamed; Colm Bergin; Fiona Lyons; Thomas R Rogers; Brian O'Connell; Emma Devitt
Journal:  J Fungi (Basel)       Date:  2021-05-28

Review 10.  Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis.

Authors:  Zorica Jović; Slobodan M Janković; Dejana Ružić Zečević; Dragan Milovanović; Srđan Stefanović; Marko Folić; Jasmina Milovanović; Marina Kostić
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-04       Impact factor: 2.569
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.